Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03540134 · ClinicalTrials.gov registry record · NA

Convection Enhanced Delivery of CSF in DBS for Parkinson's

A NA study of Parkinson Disease, sponsored by Jeff Elias, MD.

Completed
Registry status
NA
Development phase
4
Enrollment target
1
Study location

NCT03540134 is a NA study of Parkinson Disease that has completed, run by Jeff Elias, MD. The registered enrollment target is 4 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03540134, a NA study of Parkinson Disease, has completed, sponsored by Jeff Elias, MD.

COMPLETED
Registry status
NA
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate safety foremost but also the distribution and initial effectiveness of infusion-enhanced, MRI-guided DBS for patients with medication-refractory, Parkinson's disease

Conditions Studied

Interventions

  • DEVICE Intracerebral Infusion of Autologous Cerebral Spinal Fluid

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2018-02-13
Est. Completion 2018-12-18
Phase NA

Sponsor

Jeff Elias, MD

2 total trials

What the Registry Record Tells You About NCT03540134

The ClinicalTrials.gov registry entry for NCT03540134 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The listed sponsor is Jeff Elias, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Intracerebral Infusion of Autologous Cerebral Spinal Fluid is the first listed.

NCT03540134 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT03540134 about?

NCT03540134 is a clinical study titled "Convection Enhanced Delivery of CSF in DBS for Parkinson's". This study will evaluate safety foremost but also the distribution and initial effectiveness of infusion-enhanced, MRI-guided DBS for patients with medication-refractory, Parkinson's disease

What is the current status of trial NCT03540134?

This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2018-02-13. Estimated completion is 2018-12-18.

What conditions does trial NCT03540134 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT03540134?

The interventions under investigation include: Intracerebral Infusion of Autologous Cerebral Spinal Fluid (DEVICE).

Who is sponsoring clinical trial NCT03540134?

This trial is sponsored by Jeff Elias, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03540134 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.